Kyrillus S Shohdy (Kyrillus Shohdy)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 6

Top Topics

Radiation Induced

Sentinel Lymph Node

Neoadjuvant Chemotherapy

Locally Advanced

Top Venues

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals

Journal of the Egyptian National Cancer Institute

Expert opinion on therapeutic targets

This page only lists publications with an associated author ORCID identifier.

Publications

Kyrillus S Shohdy, Manon Pillai, Ryan Guest, Dominic Rothwell, Natalia Kirillova, Shien Chow, David Gilham, Fiona Thistlethwaite, Robert Hawkins
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies. EJHaem 4 (3) (2023)
Hamdy A Azim, Kyrillus S Shohdy, Hagar Elghazawy, Monica M Salib, Doaa Almeldin, Loay Kassem
Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 27 (8) (2022)
Kyrillus S Shohdy, Doaa S Almeldin, Madonna A Fekry, Mahmoud A Ismail, Nedal A AboElmaaref, Esraa G ElSadany, Baher M Hamza, Fatma H El-Shorbagy, Ahmad S Ali, Hanaa Attia, Loay Kassem
Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: a single-institute experience. Journal of the Egyptian National Cancer Institute 33 (1) (2021)
Kyrillus S Shohdy, Hanaa Attia, Neven Mahmoud, Loay Kassem
Primary primitive neuroectodermal tumor of the breast: Analysis of clinical outcomes of twenty-one patients. The breast journal 26 (9) (2020)
Kyrillus S Shohdy, Omar Abdel-Rahman
The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma. Expert review of respiratory medicine 13 (6) (2019)
Kyrillus S Shohdy, Panagiotis J Vlachostergios, Raafat R Abdel-Malek, Bishoy M Faltas
Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma. Expert opinion on therapeutic targets 23 (2) (2018)